Zacks Research Brokers Decrease Earnings Estimates for RDY

Dr. Reddy’s Laboratories Ltd (NYSE:RDY) – Research analysts at Zacks Research reduced their FY2026 earnings estimates for shares of Dr. Reddy’s Laboratories in a research note issued to investors on Wednesday, February 11th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.64 for the year, down from their prior forecast of $0.69. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2026 earnings at $0.09 EPS, Q2 2027 earnings at $0.17 EPS, Q3 2027 earnings at $0.13 EPS, Q4 2027 earnings at $0.09 EPS, FY2027 earnings at $0.56 EPS, Q3 2028 earnings at $0.16 EPS and FY2028 earnings at $0.63 EPS.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Wednesday, January 21st. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. The business had revenue of $969.81 million for the quarter, compared to analysts’ expectations of $963.84 million. Dr. Reddy’s Laboratories had a return on equity of 15.89% and a net margin of 16.41%.

Separately, Weiss Ratings raised shares of Dr. Reddy’s Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, January 30th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Dr. Reddy’s Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $16.90.

Dr. Reddy’s Laboratories Price Performance

NYSE:RDY opened at $14.22 on Thursday. The company has a 50 day moving average price of $13.78 and a 200-day moving average price of $14.02. The firm has a market cap of $11.87 billion, a price-to-earnings ratio of 18.47, a price-to-earnings-growth ratio of 12.51 and a beta of 0.35. Dr. Reddy’s Laboratories has a 1-year low of $12.26 and a 1-year high of $16.17. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.88 and a quick ratio of 1.38.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Hedge funds have recently modified their holdings of the company. Westside Investment Management Inc. acquired a new position in Dr. Reddy’s Laboratories in the 2nd quarter valued at about $35,000. EverSource Wealth Advisors LLC lifted its holdings in Dr. Reddy’s Laboratories by 71.7% in the second quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock valued at $47,000 after acquiring an additional 1,294 shares during the last quarter. Larson Financial Group LLC grew its position in Dr. Reddy’s Laboratories by 81.5% in the fourth quarter. Larson Financial Group LLC now owns 3,173 shares of the company’s stock worth $45,000 after acquiring an additional 1,425 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of Dr. Reddy’s Laboratories by 217.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,568 shares of the company’s stock worth $50,000 after acquiring an additional 2,444 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Dr. Reddy’s Laboratories during the second quarter worth about $67,000. Hedge funds and other institutional investors own 3.85% of the company’s stock.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.